Abstract: The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007. Earlier, we reported on the ENGOT minimal requirements for trials between academic groups and pharmaceutical companies. In this paper, we summarize the roadmap for performing trials in the ENGOT framework. In this roadmap, we define how an ENGOT trial should be set up and discuss the following items: What are the conditions to classify a study as an ENGOT trial? What is an ENGOT protocol? How are an ENGOT protocol, informed consent (ICF), and case report form (CRF) produced? How is the center selection and feasibility performed in ENGOT trials? How are regulatory and operational tasks handled? How should a confidentiality agreement between the industry and the whole ENGOT network be negotiated? How are contracts made between the industry and ENGOT and between ENGOT groups? How are funding, insurance, and communication flow arranged in ENGOT trials? What are the requirements for conducting substudies and what are the tasks for the leading group in an ENGOT trial? A template of a confidentiality agreement, a checklist of ENGOT criteria for new study proposals, and guidelines for authorship are also provided.
T he European Network for Gynaecological Oncological Trial groups (ENGOT
) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007. Earlier, we reported on the ENGOT minimal requirements for trials between academic groups and pharmaceutical companies. 1 In this paper, we summarize the roadmap for performing trials in the ENGOT framework.
1. What are the conditions to classify a study as an ENGOT trial? ¡ There is an ENGOT lead group ¡ Preference to join the study will be given to other ENGOT groups. ¡ It is possible for groups who are not part of the ENGOT collaboration to join an ENGOT trial. ¡ What if other non-ENGOT isolated centers wish to join the study? This is possible (see ENGOT minimal requirements for a trial 1 ).
However: 1. Most of the centers and the recruited patients are estimated to come from ENGOT group centers. This is not necessarily applicable for academic studies (ie, those without industry partner as sponsor). 2. Other centers should be approved by the ENGOT lead group or adopted by one of the participating ENGOT groups. 3. Flexibility on both requirements 1 and 2 is possible.
& In principle, it will not be possible to run a trial without the cooperation of the local ENGOT group in one of the countries represented in ENGOT. However, if isolated centers affiliated to the local ENGOT group want to do the study and there is approval of the local ENGOT group, this might be possible. & If a national or regional ENGOT group is performing a study in cooperation with the industry, it is not possible for individual non-ENGOT institutions from that country or region to join the study outside the ENGOT collaboration. & There should be at least cooperation between 2 ENGOT groups to call a trial an ENGOT trial. & In principle, the principal investigator should be appointed by the leading ENGOT group. However, in exceptional circumstances, ENGOT can decide to accept a principal investigator not belonging to ENGOT. 2. How is the center selection and feasibility performed in ENGOT trials? & When an ENGOT group is represented in a country and an interest in the trial has been expressed, the trial should be coordinated with the ENGOT group in that country. The ENGOT requirements should be discussed first before the collaboration between the ENGOT groups and an industry partner (technical or other staffing resources: aside from investigator, the center also has a study coordinator or study nurse to handle documentation and organization of the study. & Center is willing to conduct clinical trials according to the protocol and the principles of International conference on harmonization good clinical practice (ICH-GCP), local rules and regulations including documented GCP training (as applicable). & Center has the adequate infrastructure resources (laboratory, radiology, etc.) to conduct the trial according to the protocol (to be defined per protocol).
3. How are contracts made between the industry and ENGOT and between different ENGOT group? 1. Initially, an LOI describing the development of the protocol discussion should be in place. This could be an independent contract or an LOI with the specific tasks documented. It should be mentioned that the ENGOT group name should appear in every presentation and publication. 2. Minimal requirements for the contract between the lead ENGOT group and the industry partner are: ¡ Ownership and publication rights for trials between academic groups and industry partners should be mentioned in the main contract between the lead ENGOT group and the industry partner based on the chosen model of collaboration.
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¡ The clinical study database should be the property Each cooperating group should obtain insurance or indemnity for all of the trials that they are collaborating in. 5. Requirements for conducting sub-studies in an ENGOT trial The main results of the study will be the responsibility of the trial writing committee, which will have input from the study investigators, biostatisticians, data management, and (if appropriate) clinical epidemiologists. However, after the final analysis has been performed, interested cooperating groups can seek to use the data or human biological materials to generate new hypotheses and/or explore relationships between clinical, biomarkers, quality of life, and patient-related characteristics and outcomes.
The following principles are proposed to ensure that appropriate substudies are undertaken on behalf of the group together with a high quality of statistical analysis and a balanced interpretation of the results:
The steering committee of the main study as a whole or a working group set up by the steering committee for this purpose will decide whether a substudy is appropriate. The steering committee or working group will review all proposals and evaluate the feasibility of the substudy. The methodology and analysis plan should be agreed on before granting the material. The complete roadmap for ENGOT trials including also guidelines on an ENGOT protocol, informed consent form, regulatory issues, operational tasks, insurance, authorship, case report forms, tasks for the lead group, a template of a confidentiality agreement, and a checklist of criteria for new study proposals can be downloaded at http://www.esgo.org/ Documents/ENGOT_Roadmap_for_trials_version01.06.12.pdf
